ASignal is a systematic stock analysis platform that evaluates every stock through three independent investment frameworks - Buffett (value), Ackman (activist), and Dalio (macro) - with an adversarial challenger review and algorithmic confidence scoring. It produces the ASignal Rank (1-4) for each analyzed stock.

How does ASignal Rank work?

ASignal Rank is a 1-4 scoring system: 1 = Strongest data alignment, 2 = Positive alignment, 3 = Neutral, 4 = Negative alignment. These represent how strongly our analytical frameworks agree on the direction of publicly available data. It is computed by 10+ analysis agents evaluating technical indicators, fundamentals, sentiment, and three investor frameworks, then stress-tested by an adversarial challenger agent.

How much does ASignal cost?

ASignal offers a free tier. The Signal plan costs $19/month or $180/year ($15/month equivalent, 21% discount). The free tier includes 24-hour full access on signup, then top-15 daily research summaries on a 7-day delay, while paid subscribers get real-time access.

What stocks does ASignal analyze?

ASignal analyzes S&P 500 stocks daily plus trending stocks discovered from Reddit, market movers, financial news, and social media. Each stock runs through a 5-phase pipeline: data collection, analysis, multi-strategist evaluation, adversarial review, and final decision.

Is ASignal better than Seeking Alpha or TipRanks?

ASignal uses a multi-framework analysis pipeline with 10+ specialized agents including an adversarial challenger, while Seeking Alpha relies on human analysts and TipRanks aggregates Wall Street consensus. ASignal is priced at $19/month versus Seeking Alpha at $25/month and TipRanks at $30/month, and provides transparent reasoning for every signal.

Is ASignal financial advice?

No. ASignal is not a registered investment advisor, broker-dealer, or financial planner. ASignal is a data research tool that aggregates publicly available financial data for informational and educational purposes only. All scores, analyses, and reports reflect algorithmic output - not personalized investment recommendations. Always do your own research and consult a licensed financial professional before making investment decisions.

Bristol-Myers Squibb CompanyBMY

Healthcare

Neutral

ASignal's systematic analysis rates BMY as Neutral. Bristol-Myers Squibb Company has a market cap of $119.91B, a P/E of 15.96, a 15.0% net margin, and 2.6% year-over-year revenue growth.

Reflects the latest available analysis · analyzed Jul 16, 2026

The case on BMY

Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.

Bull case

Positive MACD histogram indicating strengthening bullish momentum
Price above 20-day and 50-day moving averages suggesting uptrend
Strong operating and gross margins indicating pricing power
High return on equity (38.73%) signaling efficient capital use
Attractive forward P/E of 9.48x relative to sector and growth rate
Free cash flow of $9.85B supports dividend and buyback capacity

Bear case

Debt-to-equity ratio of 2.31x is elevated, indicating higher financial risk
Revenue growth of 2.6% is relatively low, suggesting limited top-line expansion
RSI at 62.21 approaching overbought territory, limiting near-term upside
No Reddit mentions, indicating lack of retail investor interest or potential visibility issues
Dividend yield of 442% is abnormally high, likely due to data error or special distribution

Key facts

Sector

Healthcare

Market cap

$119.91B

P/E ratio

15.96

Gross margin

72.0%

Net margin

15.0%

Rev growth YoY

2.6%

Price (Jul 16, 2026)

$58.72

Peers

Clustered with BMY by analysis-profile similarity.

TMO PFE MCK LH JNJ

Subscriber-only

See the full verdict on BMY

ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.

Open full analysis →Pricing

How ASignal analyzes BMY

Most investors never get a second opinion, let alone several. ASignal runs BMY past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.

The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.